TD Cowen Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $65

Moomoo News11:31 ET · Ratings

TD Cowen Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

TipRanks11:05 ET · Ratings

Rhythm Pharmaceuticals Reports Preliminary Q4 IMCIVREE Revenue $42M

TipRanksJan 10 07:36 ET

Express News | RPT-Rhythm Pharmaceuticals: Plan to Initiate New Phase 2 Trial Exploring Setmelanotide in Prader-Willi Syndrome

ReutersJan 10 07:25 ET

Express News | Rhythm Reports Preliminary Unaudited Net Revenues From Global Sales Of IMCIVREE Of $42M For Q4, Up 26% Q/Q

BenzingaJan 10 07:23 ET

Express News | Rhythm Pharmaceuticals Inc: Net Rev FY24 Expected to Be About $130 Mln

ReutersJan 10 07:19 ET